Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019

IMPORTANCE: The introduction of biosimilars and novel delivery devices between 2014 and 2019 may have changed the utilization of granulocyte colony-stimulating factors (G-CSF). OBJECTIVE: To assess utilization trends of G-CSFs for primary prophylaxis of febrile neutropenia (FN) among patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ching-Yu, Heldermon, Coy D., Vouri, Scott M., Park, Haesuk, Wheeler, Sarah E., Ramnaraign, Brian Hemendra, Dang, Nam Hoang, Brown, Joshua D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611485/
https://www.ncbi.nlm.nih.gov/pubmed/34812849
http://dx.doi.org/10.1001/jamanetworkopen.2021.33474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611485/
https://www.ncbi.nlm.nih.gov/pubmed/34812849
http://dx.doi.org/10.1001/jamanetworkopen.2021.33474

Ejemplares similares